Yttrium (90Y) tacatuzumab tetraxetan: Difference between revisions

From Wikipedia, the free encyclopedia

Content deleted Content added

Inline

Latest revision as of 06:30, 31 December 2023

Yttrium (⁹⁰Y) tacatuzumab tetraxetan
Monoclonal antibody

Type	Whole antibody
Source	Humanized (from mouse)
Target	α-fetoprotein
Clinical data
ATC code	none
Identifiers
CAS Number	476413-07-7^N
ChemSpider	none
UNII	GJ2416WK6Y
Chemical and physical data
Formula	C₆₄₇₀H₉₉₇₁N₁₇₁₂O₂₀₀₇S₄₂⁹⁰Y
Molar mass	145 kg/mol
^NY (what is this?) (verify)

Yttrium (⁹⁰Y) tacatuzumab tetraxetan is an investigational humanized monoclonal antibody intended for the treatment of cancer.^[1] The antibody itself, tacatuzumab, is conjugated with tetraxetan, a chelator for yttrium-90,^[2] a radioisotope which destroys the tumour cells.

References[edit]

^ "Statement On A Nonproprietary Name Adopted By The USAN Council". 4 September 2004. Archived from the original on 2004-09-11.
^ WHO Drug Information

Monoclonal antibodies for tumors

Tumor

Human	Adecatumumab^§ Amivantamab Ascrinvacumab^§ Atezolizumab Balstilimab^† Botensilimab Cixutumumab^§ Conatumumab^§ Daratumumab Drozitumab^§ Duligotumab^§ Dusigitumab^§ Enfortumab vedotin Enoticumab^§ Figitumumab^§ Flanvotumab^§ Ganitumab^† Glembatumumab vedotin^† Intetumumab^§ Ipilimumab Iratumumab^§ Istiratumab Icrucumab^§ Lexatumumab^§ Lucatumumab^§ Mapatumumab^§ Narnatumab^§ Necitumumab Nesvacumab^§ Nivolumab^# Ofatumumab Olaratumab^† Panitumumab Patritumab^§ Pembrolizumab^# Pritumumab^§ Radretumab^§ Ramucirumab Rilotumumab^† Robatumumab^§ Seribantumab^§ Sugemalimab Tarextumab^§ Tisotumab vedotin Teprotumumab^† Tovetumab^§ Vantictumab^§ Votumumab^§ Zalutumumab^†
Mouse	Abagovomab Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox Moxetumomab pasudotox Naptumomab estafenatox Oregovomab Pemtumomab^† Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Nofetumomab merpentan Pintumomab Tenatumomab Tositumomab
Chimeric	Amatuximab^§ Bavituximab^§ Brentuximab vedotin Carotuximab^† Cetuximab Derlotuximab biotin^§ Dinutuximab Ecromeximab^§ Ensituximab^§ Futuximab^§ Girentuximab^† Indatuximab ravtansine^§ Isatuximab Loncastuximab tesirine Margetuximab Mirvetuximab soravtansine Rituximab^# Siltuximab Ublituximab Zolbetuximab
Humanized	Abituzumab^§ Alemtuzumab Belantamab mafodotin Bevacizumab Bivatuzumab mertansine^§ Brontictuzumab^§ Cantuzumab mertansine^§ Cantuzumab ravtansine^§ Cirmtuzumab Citatuzumab bogatox^§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab^§ Demcizumab^§ Dalotuzumab^§ Denintuzumab mafodotin^§ Elotuzumab Emactuzumab Emibetuzumab^§ Enoblituzumab^§ Epcoritamab Etaracizumab^§ Farletuzumab^§ Ficlatuzumab^§ Flotetuzumab^§ Gemtuzumab ozogamicin Glofitamab Imgatuzumab^§ Inotuzumab ozogamicin Labetuzumab^§ Lifastuzumab vedotin^§ Lintuzumab^§ Lorvotuzumab mertansine^§ Lumretuzumab^§ Matuzumab^§ Milatuzumab^§ Naxitamab Nimotuzumab^† Obinutuzumab Ocaratuzumab^§ Otlertuzumab^§ Onartuzumab^§ Oportuzumab monatox^† Parsatuzumab^§ Pertuzumab Pinatuzumab vedotin^§ Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine^† Sacituzumab govitecan Sibrotuzumab^§ Simtuzumab^§ Sofituzumab vedotin^§ Tacatuzumab tetraxetan^§ Tigatuzumab^§ Trastuzumab^# (+deruxtecan / +emtansine) Tucotuzumab celmoleukin^§ Vandortuzumab vedotin^§ Vanucizumab^§ Veltuzumab^§ Vorsetuzumab mafodotin^§
Rat/mouse hybrid	Catumaxomab Ertumaxomab^§
Chimeric + humanized	Depatuxizumab mafodotin^† Duvortuxizumab Ontuxizumab^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

This nuclear medicine article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Yttrium_(90Y)_tacatuzumab_tetraxetan&oldid=1192770004"

@@ Line 1: / Line 1: @@
+{{Short description|Monoclonal antibody}}
-{{drugbox-mab |
+{{DISPLAYTITLE:Yttrium (<sup>90</sup>Y) tacatuzumab tetraxetan}}
-| image =
+{{Drugbox
-| source = [[Human]]
+| Verifiedfields = changed
-| target =
+| Watchedfields = changed
-| CAS_number        = 476413-07-7
+| verifiedrevid = 470635003
-| ATC_prefix        =
+| image = Y-90 tacatuzumab tetraxetan structure.svg
-| ATC_suffix        =
+| drug_name = Yttrium (<sup>90</sup>Y) tacatuzumab tetraxetan
-| PubChem           =
+<!-- Monoclonal antibody data -->
-| DrugBank          =
+| type = mab
-| chemical_formula  = C<sub>6470</sub>H<sub>9971</sub>N<sub>1712</sub>O<sub>2007</sub>S<sub>42</sub><sup>90</sup>Y
+| mab_type = mab
-| molecular_weight  =
+| source = zu/o
-| bioavailability   =
+| target = [[α-fetoprotein]]
-| protein_bound     =
+<!-- Clinical data -->
-| metabolism        =
+| tradename =
-| elimination_half-life =
-| excretion         =
+| pregnancy_AU =
-| pregnancy_AU      =
+| pregnancy_US =
-| pregnancy_US      =
+| pregnancy_category =
+| legal_AU =
-| pregnancy_category=
-| legal_AU          =
+| legal_CA =
-| legal_CA          =
+| legal_UK =
-| legal_UK          =
+| legal_US =
-| legal_US          =
+| legal_status =
-| legal_status      =
 | routes_of_administration =
+<!-- Pharmacokinetic data -->
+| bioavailability =
+| protein_bound =
+| metabolism =
+| elimination_half-life =
+| excretion =
+<!-- Identifiers -->
+| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
+| ChemSpiderID = none
+| CAS_number_Ref = {{cascite|changed|??}}
+| CAS_number = 476413-07-7
+| UNII_Ref          = {{fdacite|correct|FDA}}
+| UNII              = GJ2416WK6Y
+| ATC_prefix = none
+| ATC_suffix =
+| PubChem =
+| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
+| DrugBank =
+<!-- Chemical data -->
+| chemical_formula = C<sub>6470</sub>H<sub>9971</sub>N<sub>1712</sub>O<sub>2007</sub>S<sub>42</sub><sup>90</sup>Y
+| molecular_weight = 145
+| molecular_weight_comment = kg/mol
 }}
+'''Yttrium (<sup>90</sup>Y) tacatuzumab tetraxetan''' is an investigational [[humanized monoclonal antibody]] intended for the treatment of cancer.<ref>{{cite web|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/yttrium_90_tacatuz.doc|url-status=dead|archive-url=https://web.archive.org/web/20040911162110/http://www.ama-assn.org/ama1/pub/upload/mm/365/yttrium_90_tacatuz.doc|date=4 September 2004 |title=Statement On A Nonproprietary Name Adopted By The USAN Council|archive-date=2004-09-11 }}</ref> The antibody itself, tacatuzumab, is conjugated with [[tetraxetan]], a [[chelator]] for [[yttrium-90]],<ref>[https://web.archive.org/web/20110705093023/http://apps.who.int/medicinedocs/documents/s14179e/s14179e.pdf WHO Drug Information]</ref> a [[radioisotope]] which destroys the tumour cells.
-'''Tacatuzumab tetraxetan''' is a [[Humanize|humanized]] [[monoclonal antibody]] used to treat cancer. Tacatuzumab has a [[chelator]], [[tetraxetan]]. It has a [[radioisotope]], [[yttrium]]-90Y.
+==References==
-{{monoclonal-antibody-stub}}
+{{reflist}}
-{{humanizedmonoclonals}}
+{{Monoclonals for tumors}}
-[[Category:Monoclonal antibodies]]
-[[Category:Cancer treatments]]
+{{DEFAULTSORT:Yttrium Tacatuzumab Tetraxetan}}
+[[Category:Monoclonal antibodies for tumors]]
+[[Category:Antibody-drug conjugates]]
+[[Category:Radiopharmaceuticals]]
+[[Category:Yttrium compounds]]
+[[Category:Experimental cancer drugs]]
+[[Category:DOTA (chelator) derivatives]]
+{{monoclonal-antibody-stub}}
+{{antineoplastic-drug-stub}}
+{{nuclear-med-stub}}